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Review Series: New Features of Systemic Vasculitides
Pathogenesis and Diagnosis of Otitis
Media with ANCA-Associated
Vasculitis
Naohiro Yoshida1 and Yukiko Iino1
ABSTRACT
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is histologically characterized by sys-
temic necrotizing vasculitis and is clinically classified into two phases, systemic or localized. Recently, otologi-
cal symptoms such as otitis media and hearing loss, not previously often associated with AAV, have been re-
ported in AAV cases. In these cases we propose a diagnosis of otitis media with AAV (OMAAV). The ANCA
titer is important for the diagnosis of OMAAV, and in most cases rapid progressive hearing loss is observed as
localized AAV. Peripheral facial nerve palsy or hypertrophic pachymeningitis are coupled with 25% of cases
and 18% of cases respectively. Proteinase 3-ANCA (PR3-ANCA) positive otitis media causes granulomatous
formation or middle ear effusion in the middle ear, on the other hand myeloperoxidase-ANCA (MPO-ANCA)
positive otitis media predominantly presents as otitis media with effusion. The early diagnosed case and the
sensorineural hearing loss not progressed deaf could be recovered by the immunosuppressive therapy. De-
layed diagnosis of AAV occasionally leads to progression to the irreversible phase; therefore, diagnosis at the
early-localized stage is important for treating AAV. In this review, we discuss the current understanding of this
newly proposed concept of OMAAV.
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ABBREVIATIONS
ANCA, antineutrophil cytoplasmic antibody; AAV, ANCA-associated vasculitis; GPA, granulomatosis with poly-
angiitis; MPA, microscopic polyangiitis; EGPA, eosinophilic granulomatosis polyangiitis; OMAAV, otitis media
with ANCA-associated vasculitis; MPO-ANCA, myeloperoxidase ANCA; PR3-ANCA, proteinase 3 ANCA;
OMG, otitis media with granulation; OME, otitis media with effusion; EOM, eosinophilic otitis media; ELISA,
enzyme-linked immunosorbent assay.
INTRODUCTION
Antineutrophil cytoplasmic antibody (ANCA) has
been recognized as the antibody against neutrophil
and monocyte lysosomal enzymes, in particular
myeloperoxidase (MPO) and proteinase 3 (PR3).1,2
ANCA is considered as a pathogen releasing lytic en-
zymes that cause vascular inflammation involving re-
active oxygen species and lead to systemic vasculi-
tis.3 ANCA-associated vasculitis (AAV) is histologi-
cally characterized by systemic necrotizing vasculitis
and remains a significant cause of fatal disease de-
spite progress in immunosuppressive therapy. AAV is
classified into categories based on histological fea-
tures and vessel size, from largest to smallest.4 In
small vessels, AAV comprises granulomatosis with
polyangiitis (GPA; formerly Wegener’s granulomato-
sis), microscopic polyangiitis (MPA) and eosinophilic
granulomatosis polyangiitis (EGPA; formerly Churg-
Strauss syndrome).4-7 GPA is defined as a necrotizing
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granulomatous in the nose, ear, upper respiratory or-
gan and lung. MPA is defined as a necrotizing vascu-
litis of small vessels and includes a renal subcategory
known as idiopathic necrotizing crescentic glomeru-
lonephritis. EGPA is defined as an eosinophilic in-
flammation including severe bronchial asthma,
chronic rhinosinusitisnasal polyps and eosinophilic
bronchitispneumonia, and eosinophilia.6
Systemic AAV presents otologic symptoms in 19-
61% of cases during its clinical course, whereas, less
common localized AAV presents only otologic symp-
toms such as otitis media and hearing loss, aural full-
ness, tinnitus and vertigo, initially.8-10 Delayed diag-
nosis of AAV occasionally leads to progression to the
irreversible phase; therefore, diagnosis at the early-
localized stage is important for treating AAV.
In cases of etiology unknown intractable otitis me-
dia in which known diseases, such as a bacterial otitis
media, cholesterol granuloma, malignant osteomyeli-
tis, tuberculosis, neoplasm and eosinophilic otitis me-
dia (EOM), have been ruled out, the symptoms often
indicate otitis media with AAV (OMAAV). In this re-
view article, we summarize the current understand-
ing of the clinical course and diagnosis of this newly
proposed concept of OMAAV.
DIAGNOSTIC INFORMATION REGARDING
SYSTEMIC AND LOCALIZED AAV
Two sets of diagnostic information are available with
regard to GPA: 1) the American College of Rheuma-
tology (1990) classified a typical case of GPA and pro-
vided the basic and clinical research relating to such
a case; 2) the Chapel Hill Consensus Conference de-
fined the concept of vasculitis.4,7 The classification for
GPA proposed by the American College of Rheuma-
tology, which did not include MPA or ANCA, in-
cludes four criteria: 1) nasal or oral inflammation with
oral ulcers or purulent or bloody nasal discharge; 2)
abnormal chest radiograph showing the presence of
nodules, fixed infiltrates, or cavities; 3) microhema-
turia or red blood cell casts in urine sediment; 4) his-
tologic changes showing granulomatous inflamma-
tion within the wall of an artery or perivascular or ex-
travascular area in biopsy samples.7 In 2012, the
Chapel Hill Consensus Conference proposed the re-
vised nomenclature of vasculitides.6
The histopathological identification of necrotizing
vasculitis is the key to diagnosis of AAV.4-6 However,
in many cases there are difficulties obtaining suitable
specimens for histopathologic study because of the
anatomical location and limitations regarding sample
size. A biopsy from a middle ear specimen showed a
lower positive rate compared to the other specimen
taken from nose or lung.11-13 Therefore, clinical symp-
toms and an elevation of proteinase 3 ANCA (PR3-
ANCA) andor myeloperoxidase ANCA (MPO-
ANCA) titers are important factors in the diagnosis of
AAV.6
The sensitivity of the titers of PR3- and MPO-
ANCA is different in GPA, MPA and EGPA. For GPA,
PR3-ANCA has 66% sensitivity and MPO-ANCA has
24% sensitivity; for MPA, PR3-ANCA has 26% sensitiv-
ity and MPO-ANCA has 50-80% sensitivity3,4,14,15; and
for EGPA, PR3-ANCA has 2-3% sensitivity and MPO-
ANCA has 30-40% sensitivity.16-18 MPO-ANCA-
positive EGPA showed similar clinical features to
MPA with kidney dysfunction, peripheral neuropa-
thy, alveolar hemorrhage and purpura, whereas PR3-
ANCA-positive EGPA showed granulomatous forma-
tion with peripheral neuropathy, similar to GPA.18
The main target organs involved in GPA are the
ear, nose, throat, upper respiratory tract (85-95%),
glomerulonephritis of the kidneys (40-70%) and the
lungs (40-60%).19 AAV commonly manifests as a rap-
idly progressive glomerular nephritis with necrotiz-
ing glomerular tufts, alveolar hemorrhage or intersti-
tial pneumonia, and therefore the patient is often di-
agnosed with a systemic condition. However, some
cases of AAV show only localized disease in the ear
andor nose. Nasal symptoms such as rhinorrhea, na-
sal granulation, nasal crusts, epistaxis and septum
perforation are common initial signs.7 One-third of
GPA cases present with otitis media during the clini-
cal course of AAV.11,20
Localized GPA is considered to be a short-term dis-
ease stage that occurs early on in the clinical course
of the disease and limited expression to the upper or
lower respiratory tract.6,21 Most patients present to
the clinician at the systemic stage of the disease al-
ready showing lung or kidney dysfunction, but it may
take time to reach a final diagnosis of AAV if the
signs had not been detected at the localized stage.22
Long-term follow-up of localized GPA has indicated
that 10% of patients develop systemic disease and 46%
relapse despite immunosuppressive therapy.21
Hearing loss has been reported in the clinical
course of AAV, but only recently as an early-stage
symptom.10,11,23-33 Table 1 shows the 41 OMAAV
cases reported in the English literature that pre-
sented at an early phase or were initially diagnosed
by otologic symptoms. Of these 41 cases, 12 were
male and 29 were female, with ages ranging from 20
to 77 years, and 20 were PR3-ANCA positive and 21
were MPO-ANCA positive. In addition to these cases,
the OMAAV working group in Japan reported 90
cases, including 8 cases reported previously,33 that
were preliminarily analyzed for the clinical features of
OMAAV.34 A total of 123 cases (35 male and 88 fe-
male, with ages ranging from 20 to 85 years) showed
the clinical features of OMAAV.10,11,23-34 The diagno-
sis of GPA can be difficult and in most cases can only
be provided by histological examination. Of the 123
cases, 16% were GPA positive by histological exami-
nation, without any systemic symptoms, and 87%
were ANCA positive. Of the ANCA-positive cases, 33%
were PR3 positive and 53% were MPO positive, only
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Table　1　Otitis media with ANCA-associated vasculitis presented at an early stage or initially diagnosed by otological symp-
toms, as reported in the English literature
Authors, 
Published year
Number of 
Cases 
(Gender)
Age PR3-ANCA
MPO-
ANCA
Hearing 
Loss
Ear 
Symptom
Facial 
Palsy Therapy
Hearing 
Outcome
Maguchi S et al. 
2001
1 (Male) 36 Negative Positive Mixed Tinnitus None mPSL Recovered
Takagi D et al. 
2002
7 (Male 3, 
Female 4)
20-71 7 Positive Negative 6 Mixed
1 SNHL
7 COM 1 case PSL + CPA 3 Recovered
2 No change, 
2 Dead 
(complication)
Takagi D et al. 
2004
6 (Male: 1, 
Female: 5)
36-82 Negative 6 Positive 5 Mixed
1 SNHL
5 OME 1 case PSL Complete 
recovered to 
No change
Ferri E et al. 2007 1 (Female) 59 Positive Negative Con-
ductive
OME Yes PSL + CPA Recovered
Sugimoto T et al. 
2007
1 (Female) 77 Negative Positive SNHL None None PSL Recovered
Tsuzuki K et al. 
2009
2 (Female) 44-50 Negative 2 Positive Mixed Tinnitus Yes Steroid 
pulse
Recovered
Yamamoto T et al. 
2011
1 (Female) 69 Negative Positive Mixed OME None mPSL Dead (SAH)
Okura T et al. 2011 1 (Female) 70 Negative Positive Mixed None None PSL Recovered to 
No change
Lim EJ et al. 2011 1 (Female) 54 Negative Positive SNHL NR None PSL + CPA Recovered
Wierzbicka M et al. 
2011
7 (Male 3, 
Female 4)
32-46 7 Positive Negative NR OM 2 cases PSL + CPA 3 Recovered, 
2 Progresse, 
2 Dead
Yamazaki H et al. 
2012
3 (Male: 1, 
Female: 2)
55-67 1 Positive 2 Positive Mixed Thick TM, 
Serous 
otorrhea
None PSL + CPA Recovered
Sriskandarajah V 
et al. 2012
2 (Male 1, 
Female1)
36-62 2 Positive Negative Mixed Intractable 
OM
None PSL + MTX Recovered
Yoshida N et al. 
2014
8 (Male 2, 
Female 6)
54-73 2 Positive 6 Positive SNHL OME
intractable 
OM
5 cases PSL + CPA Recovered to 
No change
SNHL, sensorineural hearing loss; COM, chronic otitis media; OME, otitis media with effusion; OM, otitis media; TM, tympanic membrane; 
NR, not recorded; mPSL, methylprednisolone; PSL, prednisolone; CPA, cyclophosphamide; MTX, methotrexate; SAH, subarachnoid hemor-
rhage.
1% were both PR3 and MPO positive and 13% were
both PR3 and MPO negative. This result is similar to
previously published reports that the sensitivity of
ANCA varies in relation to disease progression, with
only 60% of cases being ANCA positive in localized
GPA compared with 97% in systemic GPA.25 This
ANCA positivity also shows regional differences.
MPO-ANCA positivity is predominant in Asian coun-
tries, whereas PR3-ANCA positivity is predominant in
northern Europe, suggesting the influence of some
environmental factors such as silica, microbes or con-
comitant diseases, on the etiology of AAV disease.35
Indeed, MPA and MPO-ANCA was more common in
Japan and GPA and PR3-ANCA is more common in
the UK.36 Recently it became clear that PR3-ANCA
positive patients and MPO-ANCA positive patients
had a different genetic background.37
THE CLINICAL FEATURES OF OMAAV
Figure 1 shows a case of OMAAV initially diagnosed
by the otologic symptoms. In this typical case, a 69-
year-old man was treated for right-sided, mild hearing
loss with otorrhea for 6 months. One month later,
right-sided peripheral facial incomplete nerve paraly-
sis occurred with progressive hearing loss. The ear,
nose and throat investigation revealed right middle
ear effusion, with a right mean air conduction level of
85.0 dB and an air-bone gap of 35 dB, and a left mean
air conduction level of 26.7 dB with an air-bone gap of
10-35 dB. Histologically, no obvious necrotizing vas-
culitis was observed in the mucosa of the middle ear.
MRI with gadolinium enhancement did not demon-
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Fig.　1　Typical case of otitis media with ANCA-associated vasculitis. A 69-year-old man presenting with intractable otitis 
media and peripheral nerve palsy due to AAV. A: Temporal bone CT: Right mastoid cavity was occupied with a soft 
shadow. B: Pure tone audiogram before and after immunosuppressive therapy. Black shows audiogram before immuno-
suppressive therapy. Red shows audiogram after immunosuppressive therapy. C: Clinical course after immunosuppres-
sive therapy. Average hearing levels were recovered, and MPO-ANCA titer was returned to within the normal range.
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strate thickening of the meninges. The serologic in-
vestigation showed an elevated white blood cell count
of 11470 cellsμl (eosinophils 0.8%), the MPO-ANCA
titer was 90 EUml, no PR3-ANCA was present, and
C-reactive protein (CRP) was not elevated (0.18 mg
dl). Temporal bone CT presented a soft shadow in
the right middle ear and mastoid cavity (Fig. 1A), but
no pathology of the nose, lung or kidney was found.
Immunosuppressive therapy with prednisolone, start-
ing at 30 mg, cyclophosphamide and sulfamethoxa-
zoletrimethoprim was used. Facial palsy, hearing
level and MPO-ANCA titer returned to within the nor-
mal range following immunosuppressive therapy
(Fig. 1B, C).
The major clinical symptoms resulting in a visit to
the primary ear, nose and throat clinic in the 123
cases discussed previously were hearing loss (75%),
otalgia (12%), otorrhea (9%), aural fullness (6%), pe-
ripheral facial palsy (5%), headache (3%), tinnitus (2%)
and nasal discharge. During treatment at the ear,
nose and throat clinic, almost all patients were
treated for intractable otitis media with effusion
(OME) or chronic otitis media, or sensorineural hear-
ing loss. It took 3 months on average, and 8 years at
most, to reach a final diagnosis of OMAAV. The
symptoms for referral to the territory medical center
and the reason for suspecting OMAAV were: otitis
media 99%, hearing loss 99%, tinnitus 33%, otorrhea
30%, otalgia 30%, headache 20%, nasal symptoms 24%,
hypertrophic pachymeningitis 9% and facial palsy 19%.
The majority of cases (94%) showed sudden progres-
sive hearing loss and secretion or granulation in the
tympanic cavity (93%). A positive ANCA titer leads
relatively easily to a diagnosis of AAV; however, a
negative ANCA result can take time to reach a final
diagnosis and begin immunosuppressive therapy.34
The typical symptoms and clinical findings of
OMAAV are: 1) otitis media following sudden pro-
gressive hearing loss; 2) intractable otitis media not
effected by antibiotics and tympanic tube insertion; 3)
mostly PR3- andor MPO-ANCA positive; 4) occa-
sionally clinical complications such as facial palsy or
hypertrophic pachymeningitis; 5) tympanic mem-
brane showing a dull appearance similar to OME and
vessel dilatation of tympanic membrane ‘OME type’,
otitis media with granulation ‘OMG type’, or normal
appearance only with sensorineural hearing loss;
6) effectiveness of corticosteroid and immuno-
suppressive therapy using cyclophosphamide or
methotrexate.10,11,20,23-34
In most cases of gradual hearing loss due to effu-
sion and granulation in the middle ear, treated as an
intractable otitis media, sudden progressive hearing
loss over less than 2 months followed.10,11,20,23-34 Anti-
biotics were not effective against the ear infection,
and often bacterial examination of the otorrhea was
negative, with only normal bacterial flora being de-
tected in the middle ear. The trigger leading to sud-
Otitis Media with ANCA Vasculitis
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den hearing loss in intractable otitis media is not
clear. Several case reports have shown that ear condi-
tion progressed after myringotomy or mastoidec-
tomy.33,34,38 As the activation of neutrophils is neces-
sary for generating ANCA, invasive surgical proce-
dures or infection have the possibility of accelerating
inflammation. After starting immunosuppressive ther-
apy, ANCA titers rapidly returned to the normal
range and hearing levels improved in 67% of ears.
Those with complete loss of hearing could not re-
cover. After treatment, speech discrimination scores
improved by 85-100% in hearing-recovered cases.31,33
A retrocochlear disease resulted in poor speech dis-
crimination scores.39 Good speech discrimination af-
ter treatment might indicate that the hearing loss of
OMAAV was not due to retrocochlear deafness but
instead due to cochlear dysfunction.
Some of the clinical features differ between PR3-
ANCA positive and MPO-ANCA positive cases. PR3-
ANCA-positive cases showed ‘OMG-type’ a little bit
predominantly and ‘OME type’ symptoms, whereas
MPO-ANCA-positive cases showed predominantly
‘OME type’ symptoms.10,11,20,23-34 These otological
features were similar with the systemic AAV previ-
ously reported that granulomas were predominantly
seen in patients with PR3-ANCA positive and rarely in
patients with MPO-ANCA positive, but in a postmor-
tem study, some MPO-ANCA showed granulomatous
formation.40-43
In 25% of reported cases of OMAAV, reversible fa-
cial palsy is a symptom. In over 10% of patients, hemi
bilateral facial palsy occurred after hearing
loss.10,11,24-34 It remains unclear whether the facial
palsy occurred via an intracranial route, the fallopian
canal or the extra temporal region. Dehiscence of the
facial canal has been reported previously and is not
that rare.44 It is possible that granulation might
spread to the facial canal, leading to destruction of
the bony canal of the horizontal portion of the facial
nerve, as in the case of complete deafness by GPA re-
ported previously.45
Hypertrophic pachymeningitis is another cranial
symptom observed in some MPO-ANCA-positive pa-
tients. Otalgia was observed in 30% of patients; how-
ever, some patients complained of severe headache.
Even in cases where the ear drum does not appear
reddish or inflamed, if patients complain of a severe
headache, hypertrophic pachymeningitis should be
considered. It has been proposed that MPO-ANCA-
positive hypertrophic pachymeningitis should be
categorized as a central nervous system-limited form
of AAV. MPO-ANCA positivity 47% (1736) was more
frequent compared with PR3-ANCA positivity 11% (4
36) in cases of immune-mediated hypertrophic pachy-
meningitis among Japanese patients.46 These cases of
MPO-ANCA-positive hypertrophic pachymeningitis
showed some characteristic clinical features: 1) pre-
dominance of elderly female patients; 2) 82% diag-
nosed with GPA; 3) mostly limited to the dura mater,
upper airways, developing headaches, chronic sinusi-
tis, otitis media and mastoiditis.46
THE CONCEPT OF OMAAV
ANCA positivity is one of the important serological
findings used for the diagnosis of OMAAV, particu-
larly because of the difficulties in obtaining speci-
mens for pathohistology. ANCA titer is examined by
an enzyme-linked immunosorbent assay (ELISA);
however, this test does not always give a positive re-
sult depending on the course of the disease or the
medication used, such as a corticosteroid for hearing
loss.47 OMAAV that was initially diagnosed by
otological symptoms showed acute hearing loss in
over 90% of cases. Idiopathic sudden sensorineural
hearing loss is usually caused by a viral infection,
membrane brakes in the cochlea or by reduction or
occlusion of the microcirculation of the cochlear ar-
tery.48 Corticosteroid is generally medicated for the
idiopathic acute sensorineural hearing loss.49 This
medication of corticosteroid is also temporarily effec-
tive for hearing loss resulting from OMAAV, but also
reduced the ANCA titer. However, this steroid effect
is usually short-lived and the hearing impairment and
other systemic or cranial nerve palsies, especially fa-
cial palsy, typically relapse.10,33
A range of serological assays are used for the de-
tection of ANCA, these include an indirect im-
munofluorescence assay, an ELISA and chemilumi-
nescence enzyme immunoassay, and a new genera-
tion of serological assays such as a capture ELISA or
an anchor ELISA.47,50 The sensitivity differs among
these methods, and a negative ANCA result obtained
by one method may give a positive result after reex-
amination using another immunoassay.
There are some ANCA-negative cases in which the
clinical features of otitis media are identical to those
of ANCA-positive OMAAV cases. Treatment of these
ANCA-negative intractable otitis media cases is par-
ticularly challenging. Corticosteroid is temporarily ef-
fective; however, the negative ANCA result generally
discourages clinicians from the use of further im-
munosuppressive therapies because of their side ef-
fects. Indeed, one of our cases of intractable otitis me-
dia showed sensorineural hearing loss following pe-
ripheral facial palsy, hypertrophic pachymeningitis,
bulbs palsy and abducens nerve palsy, without ANCA
titer elevation or positive pathological findings of
AAV. This patient later died from a subarachnoid
hemorrhage resulting from dissection of the basilar
artery despite receiving intensive immunosuppres-
sive therapy.34
This proposed concept of OMAAV is shown in Fig-
ure 2. This novel concept encompasses cases of
ANCA-positive otitis media, otitis media diagnosed as
GPA, MPA or EGPA, or ANCA-negative cases.
OMAAV encompasses all patterns of hearing loss
Yoshida N et al.
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Fig.　2　Concept of otitis media with ANCA-associated vasculitis (OMAAV).
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(no effectiveness of antibiotics, tube insertion), or
otitis media already diagnosed as GPA, MPA, EGPA.
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Otitis media with effusion (OME) type
Hypertrophic pachymeningitis
Facial palsy
such as a conductive hearing loss, sensorineural
hearing loss and mixed hearing loss. PR3-ANCA posi-
tive hearing loss showed ‘OMG-type’ and ‘OME-type’
disease in the middle ear, whereas MPO-ANCA
showed predominantly ‘OME-type’ disease. Facial
nerve palsy was observed in 22% of PR3-positive cases
and 25% of MPO-positive cases, and hypertrophic
pachymeningitis was observed in 14% of PR3-positive
cases and 18% of MPO-positive cases. 10,11,20,23-34
MECHANISM OF HEARING LOSS IN OMAAV
Conductive hearing loss, sensorineural hearing loss
and mixed hearing loss are all observed in OMAAV
at different clinical phases. Conductive hearing loss is
caused by granulation and effusion in the middle ear.
Obstruction in the Eustachian tube, or vasculitis in
the middle ear mucosa, can lead to effusion in the
middle ear.51 Conductive hearing loss is recovered by
immunosuppressive therapy in most cases. In con-
trast, sensorineural or mixed hearing loss is caused
by inflammation in the inner ear leading to inner ear
dysfunction. Among MPO-ANCA-positive cases, 51%
showed mixed hearing loss and 36% showed sen-
sorineural hearing loss. Among PR3-ANCA-positive
cases, 60% showed mixed hearing loss, 38% showed
sensorineural hearing loss and 2% showed conductive
hearing loss.10,11,20,23-34
OMAAV showed reversible hearing loss in cases
where it had not progressed to complete deaf-
ness.24,33,34 The reversible nature of this hearing loss
with the onset of immunosuppressive therapy indi-
cates that the hair cells remain intact at the pre-
treatment stage. The inner ear maintains a specific
ionic balance via an ion pumping mechanism which
ensures a high level of K+ ions in the endolymph and
creates a 140-180 mV driving force by stria vascularis
for positively charged K+ ions to flow through the
stereocilia.52 Hair cells are morphologically coupled
to fibrocytes and supporting cells by gap junctions
and K+ ions recirculate from the endolymph to the
stria vascularis through hair cells and supporting
cells. Fibrocytes play an important role in ion trans-
port and the activation of fibrocytes causes pericyte
and capillary function and fibrovascular coupling,
which is important for recycling K+ ions from hair
cells.53,54
The proposed mechanism for reversible sen-
sorineural hearing loss involves homeostatic func-
tion, such as the stria vascularis or spiral ligament.
Significant hearing recovery after idiopathic sudden
sensorineural deafness is mainly observed 1-2
months after onset. However, AAV patients exhibited
considerable reversibility in hearing levels after im-
munosuppressive therapy, even after several months
of hearing loss. Inner ear infections, such as early
bacterial labyrinthitis, elevated the high threshold be-
cause of the chemotactic factors that infiltrated into
the round and oval window, the region responsible
for high frequency detection in the cochlea. The re-
covery of high frequency loss after labyrinthitis is
usually difficult. However, the air and bone hearing
thresholds at 4000 Hz and 8000 Hz were recovered af-
ter immunosuppressive therapy.
Figure 3 shows the proposed mechanism behind
hearing loss. AAV effects two sites: the middle ear in
which granulation or secretion occurs leading to con-
Otitis Media with ANCA Vasculitis
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Fig.　3　Possible mechanism of hearing loss in OMAAV. Left scheme shows the anatomy of the cochlea. Right 
scheme shows the possible mechanism of hearing loss. RW, round window; OW, oval window.
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ductive hearing loss, and the inner ear which is the
area related to sensorineural hearing loss. Conduc-
tive hearing loss caused by secretion and granulation
in the middle ear is usually recovered by immunosup-
pressive therapy in the early ‘reversible’ stage of dis-
ease. As AAV is progresses, granulation in the middle
ear spreads into the inner ear through the round and
oval windows. AAV can also effect the inner ear, most
likely the stria vascularis and capillaries. The early
’reversible’ state of sensorineural hearing loss might
be caused by a reduction in K+ ions in the endolymph
due to dysfunction of the stria vascularis where the
microcirculation networks are well developed in the
cochlea. This sustained microvasculitis might lead to
dysfunction of fibrovascular coupling following per-
manent ‘irreversible’ damage of hair cells. The tem-
poral bone histopathology of cases of complete deaf-
ness caused by GPA showed that tympanic granula-
tion and inflammatory substances also invade the in-
ner ear through the round window, the stria vascu-
laris was slightly atrophic and spiral ganglion cells
were well preserved.45
TREATMENT
The stage-dependent use of immunosuppressive
drugs, such as a cyclophosphamide or methotrexate,
has been questioned because of possible clinical com-
plications.55 Following studies that showed that glu-
cocorticoid treatment alone could not achieve com-
plete remission, combination therapy using glucocor-
ticoids and cyclophosphamide was tested and shown
to be effective.33,56,57
The European League Against Rheumatism re-
commended that AAV should be categorized accord-
ing to different levels of severity to assist treatment
decisions; a combination of cyclophosphamide and
prednisolone should be used for remission and induc-
tion in patients with AAV and renal or other organ
threatening disease, whereas a combination of
methotrexate and prednisolone should be used for re-
mission and induction in patients with AAV with non-
organ threatening or non-life threatening disease.46,58
Prednisolone (0.8-1 mgkgday) is tapered slowly
(20% reduced every month) and then maintained (5-
10 mgday) while monitoring the ANCA titer, C-
reactive protein levels and clinical conditions. Cyclo-
phosphamide was administered for 2 years. The ta-
pering of immunosuppressive therapy is important to
control AAV. ANCA titers were usually decreased by
immunosuppressive therapy. In long-term follow-up
studies of localized GPA, it has been reported that
10% of patients develop a systemic disease and 46% re-
lapse despite therapy.21 The persistence of high
ANCA titers after the induction of remission has been
associated with a strongly increased risk of relapse.59
The changes in ANCA titer levels in GPA were not as-
sociated with a shorter remission time and increases
were not associated with relapse.60 Although ANCA
titers do not strongly reflect disease activity, some
cases experienced a gradual increase in MPO-ANCA
titer 3 years after remission without any changes in
hearing or general symptoms.33 Close follow-up
would be essential for the early detection of relapse
evidenced by not only the general health of the pa-
Yoshida N et al.
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tient but also more specifically by hearing changes
and ear condition.
The sudden onset of progressive sensorineural
hearing loss was evident in most cases and is one of
the major ontological symptoms indicative of AAV.
Hearing loss was partially recovered by treatment
with corticosteroid alone.10,33 However, corticosteroid
alone could not achieve complete remission in many
cases, and relapsed cases after this therapy were pro-
gressed to severe systemic phase and resistant to im-
munosuppressive therapy and therefore difficult to
control. Initial immunosuppression therapy that in-
cludes corticosteroid, cyclophosphamide or metho-
trexate is therefore essential for achieving long-term
remission for OMAAV.
If OMAAV is suspected but the ANCA titer is nega-
tive, histology of the mastoid granulation taken by
mastoidectomy or nasal mucosa is recommended. In
a previous report, a biopsy from a middle ear speci-
men showed a lower positive rate.11-13 However, if the
ANCA titer is negative and ANCA-positive otitis me-
dia and other possibilities causing intractable otitis
media can be excluded, clinicians have the therapeu-
tic option to start immunosuppressive therapy with
prednisolone and cyclophosphamide so as not to
waste time seeking histological evidence for AAV and
trying to match disease criteria for GPA.
RELATIONSHIP BETWEEN EGPA AND
OMAAV
EGPA is a form of AAV, characterized by eosinophil
infiltration into the mucosa. EGPA is an eosinophil-
rich and necrotizing granulomatous inflammation
often involving the respiratory tract, and necrotizing
vasculitis predominantly affecting the small to me-
dium vessels, that is associated with asthma and
eosinophilia.6
The American College of Rheumatology or Lan-
ham criteria for EGPA specify an MPO-ANCA titer of
30-40%. The most common symptoms of EGPA are
bronchial asthma, eosinophilia (over 10% of periph-
eral white blood cells), single neuritis and chronic
rhinosinusitis, especially infiltrated with eosinophils.
Otitis media in EGPA patients is different from other
AAV diseases such as GPA and MPA because eosino-
philic infiltration is observed compared with neutro-
philic infiltration in GPA. EGPA patients exhibited
mucous and glue secretion in the tympanic cavity
similar to EOM. The criteria for EOM were proposed
in 2011.61 The major criterion was OME or chronic
otitis media with eosinophil-dominant effusion, the
minor criteria were: 1) highly viscous middle ear effu-
sion; 2) resistance to conventional treatment for otitis
media; 3) association with bronchial asthma; and 4)
association with nasal polyposis. Definitive cases are
positive for the major criterion plus two or more of
the minor criteria. The EOM criteria exclude EGPA
and hypereosinophilic syndrome. EOM does not
show necrotizing vasculitis in the middle ear mucosa.
Clinical features relating to eosinophil infiltration,
middle ear effusion and mucosal changes are similar
in both EOM and localized EGPA. The middle ear
mucosa of EOM contains IgE positive cells, and IgE,
RANTES and eotaxin derived from eosinophils were
detected in the middle ear effusion. The severity of
EOM correlated with the total IgE concentration in
the middle ear effusion, and antigen-specific IgE of
fungus (i.e., Aspergillus and Candida) were detected
in the middle ear effusion not in serum. Therefore,
EOM is an allergic-type disease not related to vasculi-
tis.62 The clinical features of EOM resemble localized
EGPA. During treatment for EOM, some patients
presented numbness in the leg or skin eruptions
characteristic of EGPA. It is therefore necessary to
pay close attention to the mononeuritis, polyneuritis
or skin purpura-specific nature of EGPA during diag-
nosis.
CONCLUSION
AAV diagnosed by the otological symptoms of otitis
media or hearing loss has been reported recently
more than previous reports. In cases of intractable
otitis media, previously unknown etiologies and resis-
tance to conventional therapies have been reported.
OMAAV might be one of the strong candidates to ex-
plain these discrepancies. Localized AAV can lead to
systemic AAV, which has a high rate of fatal disease
despite immunosuppressive therapy. A possibility of
OMAAV should be considered when encountering in-
tractable otitis media and progressive hearing loss.
Immunosuppressive therapy should be started as
soon as an elevated ANCA titer is detected or
matched with the clinical features of OMAAV, even in
the absence of typical histological findings. Thus, es-
tablishment of the diagnostic criteria of OMAAV ob-
tained from further analysis for many more intracta-
ble otitis media cases should be followed by the de-
velopment of its therapeutic strategies.
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